VAST THERAPEUTICS
Vast Therapeutics develops inhalable treatments for antibiotic-resistant pathogens present in cystic fibrosis and other respiratory disease patients. The company is in the preclinical stage of developing inhalable therapeutics to treat chronic infections common to the cystic fibrosis population.
VAST THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2017-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.vasttherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
919-321-1375
Email Addresses:
[email protected]
Total Funding:
16.2 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Google Analytics LetsEncrypt SSL By Default ReCAPTCHA Apache Microsoft Exchange Online
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Founder
Investors List
Collaboratory
Collaboratory investment in Grant - Vast Therapeutics
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Series A - Vast Therapeutics
Shionogi
Shionogi investment in Series A - Vast Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-03-07 | Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer |
Official Site Inspections
http://www.vasttherapeutics.com Semrush global rank: 11.13 M Semrush visits lastest month: 170
Unable to get host informations!!!
More informations about "Vast Therapeutics"
Vast Therapeutics - Vast Therapeutics
Jan 17, 2024 Vast Therapeutics Selected to Present at the American Thoracic Society (ATS)2024 Respiratory Innovation Summit in San Diego, CA April 17, 2024See details»
Breathing is Fundamental - Vast Therapeutics
Yet, there are many chronic lung diseases which strain this fundamental act. At Vast Therapeutics, we are developing breakthrough medicines to treat chronic respiratory diseases …See details»
Vast Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number 919-321-1375 Vast Therapeutics develops inhalable treatments for antibiotic-resistant pathogens …See details»
Our Team - Vast Therapeutics
Mark Schoenfisch, PH.D. Founder, Chief Scientific Officer Dr. Schoenfisch, Board Member and Founder of Vast, is the Peter A. Ornstein Distinguished Professor of Chemistry at the University of North Carolina at Chapel Hill (UNC) where he …See details»
Vast Therapeutics - LinkedIn
Vast Therapeutics | 995 followers on LinkedIn. Leveraging our proprietary nitric oxide technology to preserve lung function. | Vast is a preclinical airway immunology company focused on …See details»
Vast Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Vast Therapeutics, Inc. of Morrisville, NC. Get the latest business insights from Dun & Bradstreet.See details»
Vast Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Vast Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 news, Disease Domain:Infectious Diseases, Technology Platform:Small ...See details»
Vast Therapeutics - Overview, News & Similar companies - ZoomInfo
Jan 16, 2024 Vast Therapeutics contact info: Phone number: (919) 321-1375 Website: www.vasttherapeutics.com What does Vast Therapeutics do? Vast Therapeutics, a subsidiary …See details»
Vast Success Biotechnology Company Limited - Drug pipelines, …
We believe our product candidates may provide an effective treatment for patients infected with Pseudomonas aeruginosa, NTM, and other drug-resistant microbes. Contact: Nathan Stasko …See details»
Vast Therapeutics - Craft
Vast Therapeutics (formerly Novoclem Therapeutics) is a preclinical-stage pharmaceutical company developing a nitric oxide-based therapy to treat respiratory diseases.See details»
Vast Therapeutics Expands Leadership Team with Appointment of …
Mar 7, 2024 Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer. Dr. Bruinenberg brings over 30 years of experience as a clinical …See details»
Vast Therapeutics Expands Leadership Team with Appointment of …
Mar 7, 2024 “Paul’s development experience will guide Vast Therapeutics as we successfully transition to a clinical-stage organization,” said Nate Stasko, Chief Executive Officer at Vast …See details»
Vast Therapeutics Expands Leadership Team with Appointment
Mar 7, 2024 Addition of CMO, Medical Director Chris Polage, MD, and enhancements in clinical operations position Company for success in the clinical development of ALX1 in …See details»
Vast Therapeutics, Inc. - 药物管线_专利_临床试验_投融营收_最新药 …
We believe our product candidates may provide an effective treatment for patients infected with Pseudomonas aeruginosa, NTM, and other drug-resistant microbes. Contact: Nathan Stasko …See details»
Vast Therapeutics | CipherBio
Explore Vast Therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Policies - Vast Therapeutics
Financial Conflict of Interest Policy. Purpose. KNOW Bio, LLC and its subsidiaries, which include EmitBio, Inc., Revian, Inc., and Vast Therapeutics, Inc., (collectively, “KNOW Bio”) are …See details»
ALX-1 - Drug Targets, Indications, Patents - Synapse - Patsnap
Dec 30, 2024 ALX-1: a Nitric oxide donors Drug, Initially developed by Vast Therapeutics, Inc., Now, its global highest R&D status is Phase 1, Mechanism: Nitric oxide donors, Therapeutic …See details»
Vast Therapeutics-动脉网 - vbdata.cn
[email protected] Vast Therapeutics是KNOW Bio的子公司，前身为Novoclem Therapeutics。 该公司专注于开发一种基于一氧化氮吸入疗法的药物BIOC51，以治疗与慢性 …See details»
News - Vast Therapeutics
Jul 1, 2022 Vast Therapeutics Selected to Present at the American Thoracic Society (ATS)2024 Respiratory Innovation Summit in San Diego, CA April 17, 2024See details»
Technology - Vast Therapeutics
Vicious Cycle of Infection and Inflammation. The progression of many lung diseases that ultimately leads to loss of lung function is driven by upregulated inflammation, typically as a …See details»